A 47-year-old man with chronic back pain has not improved with NSAIDs and is not a surgical candidate. He asks for tramadol because he believes it is not an opioid.
His pain needs a plan. The decision starts with the diagnosis, previous treatment and functional goals, rather than tramadol’s reputation as a milder medicine.
First decide whether an opioid is indicated
Reassess for a new cause or complication of the back pain. Clarify what “failed NSAIDs” means: which medicine, how it was used, benefit, adverse effects and contraindications.
Persistent pain alone does not establish that an opioid will improve function. In the SPACE randomized trial, an opioid-based strategy was not superior to a nonopioid strategy for pain-related function over 12 months in 240 patients with chronic back pain or hip/knee osteoarthritis. This was primary-care evidence, not a trial of immediate ED rescue analgesia.
Avoiding tramadol does not automatically make morphine, hydrocodone or oxycodone the right next treatment.
Two mechanisms, variable response
Tramadol combines weak mu-opioid activity with inhibition of serotonin and norepinephrine reuptake. CYP2D6 converts it to O-desmethyltramadol, which has stronger mu-receptor activity. Both the parent drug and metabolite contribute to its effects.
Poor CYP2D6 metabolizers may obtain less analgesia; ultrarapid metabolizers can develop excessive opioid effects. CPIC recommends avoiding tramadol in known poor and ultrarapid metabolizers. A patient’s ancestry cannot establish their phenotype.
Medication changes matter too. CYP2D6 inhibition can reduce active-metabolite formation while increasing parent-drug exposure. Less opioid analgesia can therefore coexist with greater serotonergic or seizure risk. Review interactions before escalating an apparently ineffective dose.
At the bedside, worsening sedation or slow breathing suggests opioid toxicity. Agitation with hyperreflexia or clonus should raise concern for serotonin toxicity. Neither pattern should be dismissed as a routine analgesic adverse effect.
What the clinical trials actually show
The answer depends on the pain condition and comparator:
In a 2024 randomized trial across three EDs, 291 patients with acute low back pain and sciatica received diclofenac plus tramadol, tizanidine or placebo. Adding tramadol did not improve one-week functional recovery. Only 23.7% were fully adherent, which limits interpretation. This does not directly answer the chronic-pain case above.
Conversely, a 2007 ankle-sprain trial found tramadol/acetaminophen and hydrocodone/acetaminophen more effective than placebo, with no statistically significant efficacy difference between the active groups. It tested combination products, not tramadol alone, and does not establish identical safety.
These trials support selective prescribing. They do not justify claiming that tramadol never works or never belongs in emergency care.
Safety checks before prescribing
Tramadol can cause dependence, respiratory depression, seizures and serotonin syndrome, including at recommended doses. Review seizure history, serotonergic medicines, CNS depressants, renal/hepatic function and available CYP2D6 results.
The U.S. immediate-release tablet label contraindicates use below age 12, after tonsil/adenoid surgery below age 18, with significant respiratory depression, acute/severe asthma in an unmonitored setting or without resuscitative equipment, gastrointestinal obstruction, relevant hypersensitivity, or MAOIs within 14 days. This product is indicated for adults. Breastfeeding is not recommended. These restrictions are product- and jurisdiction-specific.
Use the complete local label for dosing and adjustments; immediate-release, extended-release and combination products are not interchangeable. Discuss overdose reversal medication and avoid abrupt discontinuation in a physically dependent patient.
Seizures are a recognized warning, but their comparative frequency is uncertain. A large observational comparison with codeine found different results depending on how seizures were defined. It cannot establish a universal risk ranking among opioids.
Choose the treatment for the patient
For the opening case, reassess the diagnosis and agree on a functional goal. Review previous treatment, appropriate nonopioid options and rehabilitation, and coordinate follow-up. The information provided does not establish a need for an opioid prescription.
For a different patient with severe acute pain, provide timely analgesia while investigating the cause. Consider condition-specific nonopioid treatment and local or regional techniques where appropriate.
If an opioid is warranted, select the agent, route and duration individually. Reassess pain relief, function, sedation and ventilation. A full agonist may be easier to titrate in some settings, but it retains serious opioid risks.
Take-home point
Tramadol is an opioid with an additional monoaminergic mechanism and clinically important metabolic variability. Prescribe it only when the expected benefit fits the pain condition and the patient’s risks. Treat pain seriously without treating a “weaker opioid” label as reassurance.
